difficulties integrating businesses we acquire ; increases or other changes in the company 's acquisition cost for its products ; increased competition from competitors having greater financial , technical , reimbursement , marketing and other resources could have the effect of reducing prices and margins ; the level of our indebtedness may limit our ability to execute our business strategy and increase the risk of default under our debt obligations , introduction of new drugs can cause prescribers to adopt therapies for existing patients that are less profitable to us ; and changes in industry pricing benchmarks could have the effect of reducing prices and margins . you should not place undue reliance on such forward-looking statements as they speak only as of the date they are made . except as required by law , we assume no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized . business overview we are a national provider of home infusion and other home healthcare services that partners with patients , physicians , hospitals , healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of cost-effective access to prescription medications and home healthcare services . our services are designed to improve clinical outcomes to patients with chronic and acute healthcare conditions while controlling overall healthcare costs . as of december 31 , 2012 , we had a total of 81 locations in 24 states encompassing 32 home nursing locations and 49 home infusion locations , including two contract affiliated infusion pharmacies . our platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch , community-based and home-based care environment . our core services are provided in coordination with , and under the direction of , a patient 's physician . our pharmacy and home health professionals , including pharmacists , nurses , respiratory therapists and physical therapists , work with the physician to develop a plan of care suited to our patient 's specific needs . whether in the home , physician office , ambulatory infusion center or other alternate sites of care , we provide products , services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as cancer , multiple sclerosis , organ transplants , bleeding disorders , rheumatoid arthritis , immune deficiencies and congestive heart failure . our business is currently reported under three segments : infusion services , home health services and pharmacy benefit management ( `` pbm `` ) services . these three segments reflect how our chief operating decision maker reviews our results in terms of allocating resources and assessing operating and financial performance . the infusion services segment provides services consisting of home infusion therapy , respiratory therapy and the provision of durable medical equipment products and services . infusion services include the dispensing and administering of infusion-based drugs , which typically require additional nursing and clinical management services , equipment to administer the correct dosage and patient training designed to improve patient outcomes . home infusion services also include the dispensing of self-injectible therapies . the home health services segment provides services which include the provision of skilled nursing services and therapy visits , private duty nursing services , hospice services , rehabilitation services and medical social services to patients primarily in their home . since the acquisition of critical homecare solutions holdings , inc. ( `` chs `` ) in march , 2010 , we have implemented certain managed care contracts across both the infusion services and home health services segments . the contracted rates have reduced reimbursement levels compared to the out-of-network reimbursement levels received prior to june , 2010 , when we began the process of moving certain out-of-network payors under national contracts . on a year-over-year basis , the contracts have reduced net revenue per patient in certain therapies and drug classes and , correspondingly , our gross profit margin and segment adjusted 38 ebitda , as defined below . however , the contract relationship allows greater access to more insured lives . we have seen sequential and year-over-year volume trends increase from these contracted relationships . the pbm services segment consists of integrated pbm services , which primarily consists of discount card programs . the discount card programs provide a cost effective alternative for individuals who may be uninsured , underinsured or may have restrictive coverage that disallows reimbursement for certain medications . under these discount programs , individuals who present a discount card at one of the company 's participating network pharmacies receive prescription medications at a discounted price compared to the retail price . in addition , in the company 's capacity as a pharmacy benefit manager , it has fully funded prescription benefit programs where the company reimburses its network pharmacies and third party payors in turn reimburse the company based on medi-span reported pricing for those claims fulfilled for their plan participants . in the fourth quarter of 2010 , we commenced a strategic assessment of our business and operations . this assessment focused on expanding revenue opportunities and lowering corporate overhead , including workforce and benefit reductions and facility rationalization . it also examined our market strengths and opportunities and compared our position to that of our competitors . as a result of the assessment , we focused our growth on investments in the infusion services and home health services segments and elected to pursue offers for a large portion of our pharmacy services segment . story_separator_special_tag allowance for contractual discounts we are reimbursed by plan sponsors for products and services we provide . payments for medications and services covered by plan sponsors are generally less than billed charges . we monitor revenue and receivables from plan sponsors on an account-specific basis and record an estimated contractual allowance for certain revenue and receivable balances at the revenue recognition date to properly account for anticipated differences between amounts billed and amounts reimbursed . accordingly , the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors . since billing functions for a portion of our revenue are largely computerized , which enables on-line adjudication ( i.e . , submitting charges to third-party payors electronically , with simultaneous feedback of the amount the primary insurance plan expects to pay ) at the time of sale to record net revenue , exposure to estimating contractual allowance adjustments is limited . for the remaining portion of our revenue , the contractual allowance is estimated based on several criteria , including unbilled and or initially rejected claims , historical trends based on actual claims paid , current contract and reimbursement terms , and changes 42 in customer base and payor/product mix . contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled . we do not believe these changes in estimates are material . amounts due to plan sponsors payables to plan sponsors primarily represent payments received from plan sponsors in excess of the contractually required reimbursement . these amounts are refunded to plan sponsors . these payables also include the sharing of manufacturers ' rebates with plan sponsors . income taxes as part of the process of preparing our consolidated financial statements , management is required to estimate income taxes in each of the jurisdictions in which we operate . we account for income taxes under asc topic 740 , income taxes ( “ asc 740 ” ) . asc 740 requires the use of the asset and liability method of accounting for income taxes . under this method , deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities . a valuation allowance is recorded against deferred tax assets when , in the opinion of management , it is more likely than not that we will not be able to realize the benefit from our deferred tax assets . a valuation allowance is reversed when sufficient evidence exists that we will be able to realize the benefits of our deferred tax assets . as of december 31 , 2012 , the company has a full valuation allowance of $ 39.7 million recorded against its deferred tax assets . we will maintain this valuation allowance until an appropriate level of profitability is sustained or we are able to develop tax planning strategies that enable us to conclude that it is more likely than not that our deferred tax assets are realizable . as of december 31 , 2012 , the company has deferred tax liabilities of $ 11.3 million relating to indefinite-lived goodwill and intangibles . these deferred tax liabilities can not be used as a future source of taxable income because of the indefinite nature of the assets and therefore can not be used to offset the deferred tax assets that require a valuation allowance . the deferred tax liability for these indefinite-lived goodwill and intangibles will continue to increase as the company continues to amortize the tax deductible amounts of these assets . the tax amortization related to these assets will increase the deferred tax liability as well as create tax expense in future years until the full valuation allowance is reversed or the asset is fully amortized for tax purposes . we file income tax returns , including returns for our subsidiaries , as prescribed by federal tax laws and the tax laws of the state and local jurisdictions in which we operate . our uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes of asc 740 are met . interest and penalties related to unrecognized tax benefits are recorded as income tax expense . goodwill and intangible assets in accordance with asc topic 350 , intangibles – goodwill and other ( “ asc 350 ” ) , we evaluate goodwill and indefinite lived intangible assets for impairment on an annual basis and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable . the goodwill valuation is based on a two-step process . the first step compares the fair value of a reporting unit with its carrying amount , including goodwill . if the first step indicates that the fair value of the reporting unit is less than its carrying amount , the second step must be performed which determines the implied fair value of reporting unit goodwill . the measurement of possible impairment is based upon the comparison of the implied fair value of reporting unit to its carrying value . we use a third party valuation specialist to assist in the annual impairment valuation . as of december 31 , 2012 , our reporting units include goodwill of $ 304.3 million in the infusion reporting unit ; goodwill of $ 33.8 million and indefinite lived assets of $ 15.4 million in the home health services reporting unit ; and goodwill of $ 12.7 million in the pbm services reporting unit . the goodwill of the infusion and home health reporting units was primarily recorded as a result of the acquisition of chs in march 2010. in performing an annual evaluation of goodwill , a reporting unit fair value is determined based on discounted future cash flows and a market-based comparison to industry peers . significant estimates used

liquidity and capital resources we utilize funds generated from operations for general working capital needs , capital expenditures and acquisitions . net cash provided by operating activities of continuing operations totaled $ 49.9 million during the year ended december 31 , 2012 compared to $ 3.1 million during the year ended december 31 , 2011. this inflow of cash from operating activities related to continuing operations for the year ended december 31 , 2012 was due to $ 101.3 million of collections on receivables offset by $ 48.2 million in payments on accounts payable , largely due to the conversion to cash of pharmacy services related receivables and payables retained upon the sale of certain of the unit 's assets . net cash used in investing activities associated with continuing operations during the year ended december 31 , 2012 was $ 67.6 million primarily due to the $ 41.4 million invested to acquire infuscience combined with a $ 10.7 million investment in an affiliated variable interest entity . there were also $ 11.0 million invested in purchases of property and equipment . this compared to a use of cash in investing activities for continuing operations during 2011 totaling $ 8.3 million , primarily related to purchases of property and equipment . net cash used in financing activities during the year ended december 31 , 2012 of $ 58.6 million reflected the payment of the outstanding balance on the line of credit at the time of the pharmacy services asset sale . net cash used in financing activities during the year ended december 31 , 2011 of $ 17.1 million reflected a reduction in the balance of the line of credit during the year .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we utilize funds generated from operations for general working capital needs , capital expenditures and acquisitions . net cash provided by operating activities of continuing operations totaled $ 49.9 million during the year ended december 31 , 2012 compared to $ 3.1 million during the year ended december 31 , 2011. this inflow of cash from operating activities related to continuing operations for the year ended december 31 , 2012 was due to $ 101.3 million of collections on receivables offset by $ 48.2 million in payments on accounts payable , largely due to the conversion to cash of pharmacy services related receivables and payables retained upon the sale of certain of the unit 's assets . net cash used in investing activities associated with continuing operations during the year ended december 31 , 2012 was $ 67.6 million primarily due to the $ 41.4 million invested to acquire infuscience combined with a $ 10.7 million investment in an affiliated variable interest entity . there were also $ 11.0 million invested in purchases of property and equipment . this compared to a use of cash in investing activities for continuing operations during 2011 totaling $ 8.3 million , primarily related to purchases of property and equipment . net cash used in financing activities during the year ended december 31 , 2012 of $ 58.6 million reflected the payment of the outstanding balance on the line of credit at the time of the pharmacy services asset sale . net cash used in financing activities during the year ended december 31 , 2011 of $ 17.1 million reflected a reduction in the balance of the line of credit during the year .
```    
 Suspicious Activity Report : difficulties integrating businesses we acquire ; increases or other changes in the company 's acquisition cost for its products ; increased competition from competitors having greater financial , technical , reimbursement , marketing and other resources could have the effect of reducing prices and margins ; the level of our indebtedness may limit our ability to execute our business strategy and increase the risk of default under our debt obligations , introduction of new drugs can cause prescribers to adopt therapies for existing patients that are less profitable to us ; and changes in industry pricing benchmarks could have the effect of reducing prices and margins . you should not place undue reliance on such forward-looking statements as they speak only as of the date they are made . except as required by law , we assume no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized . business overview we are a national provider of home infusion and other home healthcare services that partners with patients , physicians , hospitals , healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of cost-effective access to prescription medications and home healthcare services . our services are designed to improve clinical outcomes to patients with chronic and acute healthcare conditions while controlling overall healthcare costs . as of december 31 , 2012 , we had a total of 81 locations in 24 states encompassing 32 home nursing locations and 49 home infusion locations , including two contract affiliated infusion pharmacies . our platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch , community-based and home-based care environment . our core services are provided in coordination with , and under the direction of , a patient 's physician . our pharmacy and home health professionals , including pharmacists , nurses , respiratory therapists and physical therapists , work with the physician to develop a plan of care suited to our patient 's specific needs . whether in the home , physician office , ambulatory infusion center or other alternate sites of care , we provide products , services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as cancer , multiple sclerosis , organ transplants , bleeding disorders , rheumatoid arthritis , immune deficiencies and congestive heart failure . our business is currently reported under three segments : infusion services , home health services and pharmacy benefit management ( `` pbm `` ) services . these three segments reflect how our chief operating decision maker reviews our results in terms of allocating resources and assessing operating and financial performance . the infusion services segment provides services consisting of home infusion therapy , respiratory therapy and the provision of durable medical equipment products and services . infusion services include the dispensing and administering of infusion-based drugs , which typically require additional nursing and clinical management services , equipment to administer the correct dosage and patient training designed to improve patient outcomes . home infusion services also include the dispensing of self-injectible therapies . the home health services segment provides services which include the provision of skilled nursing services and therapy visits , private duty nursing services , hospice services , rehabilitation services and medical social services to patients primarily in their home . since the acquisition of critical homecare solutions holdings , inc. ( `` chs `` ) in march , 2010 , we have implemented certain managed care contracts across both the infusion services and home health services segments . the contracted rates have reduced reimbursement levels compared to the out-of-network reimbursement levels received prior to june , 2010 , when we began the process of moving certain out-of-network payors under national contracts . on a year-over-year basis , the contracts have reduced net revenue per patient in certain therapies and drug classes and , correspondingly , our gross profit margin and segment adjusted 38 ebitda , as defined below . however , the contract relationship allows greater access to more insured lives . we have seen sequential and year-over-year volume trends increase from these contracted relationships . the pbm services segment consists of integrated pbm services , which primarily consists of discount card programs . the discount card programs provide a cost effective alternative for individuals who may be uninsured , underinsured or may have restrictive coverage that disallows reimbursement for certain medications . under these discount programs , individuals who present a discount card at one of the company 's participating network pharmacies receive prescription medications at a discounted price compared to the retail price . in addition , in the company 's capacity as a pharmacy benefit manager , it has fully funded prescription benefit programs where the company reimburses its network pharmacies and third party payors in turn reimburse the company based on medi-span reported pricing for those claims fulfilled for their plan participants . in the fourth quarter of 2010 , we commenced a strategic assessment of our business and operations . this assessment focused on expanding revenue opportunities and lowering corporate overhead , including workforce and benefit reductions and facility rationalization . it also examined our market strengths and opportunities and compared our position to that of our competitors . as a result of the assessment , we focused our growth on investments in the infusion services and home health services segments and elected to pursue offers for a large portion of our pharmacy services segment . story_separator_special_tag allowance for contractual discounts we are reimbursed by plan sponsors for products and services we provide . payments for medications and services covered by plan sponsors are generally less than billed charges . we monitor revenue and receivables from plan sponsors on an account-specific basis and record an estimated contractual allowance for certain revenue and receivable balances at the revenue recognition date to properly account for anticipated differences between amounts billed and amounts reimbursed . accordingly , the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors . since billing functions for a portion of our revenue are largely computerized , which enables on-line adjudication ( i.e . , submitting charges to third-party payors electronically , with simultaneous feedback of the amount the primary insurance plan expects to pay ) at the time of sale to record net revenue , exposure to estimating contractual allowance adjustments is limited . for the remaining portion of our revenue , the contractual allowance is estimated based on several criteria , including unbilled and or initially rejected claims , historical trends based on actual claims paid , current contract and reimbursement terms , and changes 42 in customer base and payor/product mix . contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled . we do not believe these changes in estimates are material . amounts due to plan sponsors payables to plan sponsors primarily represent payments received from plan sponsors in excess of the contractually required reimbursement . these amounts are refunded to plan sponsors . these payables also include the sharing of manufacturers ' rebates with plan sponsors . income taxes as part of the process of preparing our consolidated financial statements , management is required to estimate income taxes in each of the jurisdictions in which we operate . we account for income taxes under asc topic 740 , income taxes ( “ asc 740 ” ) . asc 740 requires the use of the asset and liability method of accounting for income taxes . under this method , deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities . a valuation allowance is recorded against deferred tax assets when , in the opinion of management , it is more likely than not that we will not be able to realize the benefit from our deferred tax assets . a valuation allowance is reversed when sufficient evidence exists that we will be able to realize the benefits of our deferred tax assets . as of december 31 , 2012 , the company has a full valuation allowance of $ 39.7 million recorded against its deferred tax assets . we will maintain this valuation allowance until an appropriate level of profitability is sustained or we are able to develop tax planning strategies that enable us to conclude that it is more likely than not that our deferred tax assets are realizable . as of december 31 , 2012 , the company has deferred tax liabilities of $ 11.3 million relating to indefinite-lived goodwill and intangibles . these deferred tax liabilities can not be used as a future source of taxable income because of the indefinite nature of the assets and therefore can not be used to offset the deferred tax assets that require a valuation allowance . the deferred tax liability for these indefinite-lived goodwill and intangibles will continue to increase as the company continues to amortize the tax deductible amounts of these assets . the tax amortization related to these assets will increase the deferred tax liability as well as create tax expense in future years until the full valuation allowance is reversed or the asset is fully amortized for tax purposes . we file income tax returns , including returns for our subsidiaries , as prescribed by federal tax laws and the tax laws of the state and local jurisdictions in which we operate . our uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes of asc 740 are met . interest and penalties related to unrecognized tax benefits are recorded as income tax expense . goodwill and intangible assets in accordance with asc topic 350 , intangibles – goodwill and other ( “ asc 350 ” ) , we evaluate goodwill and indefinite lived intangible assets for impairment on an annual basis and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable . the goodwill valuation is based on a two-step process . the first step compares the fair value of a reporting unit with its carrying amount , including goodwill . if the first step indicates that the fair value of the reporting unit is less than its carrying amount , the second step must be performed which determines the implied fair value of reporting unit goodwill . the measurement of possible impairment is based upon the comparison of the implied fair value of reporting unit to its carrying value . we use a third party valuation specialist to assist in the annual impairment valuation . as of december 31 , 2012 , our reporting units include goodwill of $ 304.3 million in the infusion reporting unit ; goodwill of $ 33.8 million and indefinite lived assets of $ 15.4 million in the home health services reporting unit ; and goodwill of $ 12.7 million in the pbm services reporting unit . the goodwill of the infusion and home health reporting units was primarily recorded as a result of the acquisition of chs in march 2010. in performing an annual evaluation of goodwill , a reporting unit fair value is determined based on discounted future cash flows and a market-based comparison to industry peers . significant estimates used

